Jennison Associates LLC decreased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 93.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 650,300 shares of the biopharmaceutical company’s stock after selling 8,976,179 shares during the period. Jennison Associates LLC owned approximately 0.29% of Alexion Pharmaceuticals worth $79,122,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ALXN. DnB Asset Management AS increased its stake in shares of Alexion Pharmaceuticals by 9.9% in the first quarter. DnB Asset Management AS now owns 23,408 shares of the biopharmaceutical company’s stock valued at $2,838,000 after buying an additional 2,100 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Alexion Pharmaceuticals by 40.7% in the first quarter. Nisa Investment Advisors LLC now owns 54,205 shares of the biopharmaceutical company’s stock valued at $6,572,000 after buying an additional 15,670 shares during the period. Columbus Circle Investors increased its stake in shares of Alexion Pharmaceuticals by 21.1% in the first quarter. Columbus Circle Investors now owns 75,796 shares of the biopharmaceutical company’s stock valued at $9,190,000 after buying an additional 13,183 shares during the period. Mn Services Vermogensbeheer B.V. increased its stake in shares of Alexion Pharmaceuticals by 4.3% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 5,980 shares of the biopharmaceutical company’s stock valued at $678,000 after buying an additional 245 shares during the period. Finally, Independent Portfolio Consultants Inc. increased its stake in shares of Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 340 shares during the period. Institutional investors own 90.74% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 133.43 on Tuesday. The company’s 50 day moving average is $131.19 and its 200 day moving average is $123.04. The firm has a market cap of $29.78 billion, a price-to-earnings ratio of 57.86 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $145.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.48. The firm had revenue of $912 million during the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 7.47% and a net margin of 18.09%. The firm’s revenue was up 21.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.13 earnings per share. Analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Jennison Associates LLC Sells 8,976,179 Shares of Alexion Pharmaceuticals, Inc. (ALXN)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/22/jennison-associates-llc-sells-8976179-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Several equities research analysts recently issued reports on ALXN shares. BMO Capital Markets reiterated an “outperform” rating and issued a $158.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Raymond James Financial, Inc. reiterated a “strong-buy” rating and issued a $176.00 target price on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 9th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $142.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday, June 9th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 target price for the company in a research note on Wednesday, August 2nd. Finally, Leerink Swann reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 23rd. Six investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $156.13.

In other news, Director Bros. Advisors Lp Baker purchased 1,348,955 shares of the business’s stock in a transaction on Wednesday, June 14th. The shares were bought at an average price of $116.32 per share, with a total value of $156,910,445.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the transaction, the director now directly owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 2,019,734 shares of company stock worth $235,606,846. 4.35% of the stock is currently owned by corporate insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.